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SObjective: To create a model for perioperative risk of esophagectomy for cancer using the Society of Thoracic
Surgeons General Thoracic Database.
Methods: The Society of Thoracic Surgeons General Thoracic Database was queried for all patients treated with
esophagectomy for esophageal cancer between January 2002 and December 2007. A multivariable risk model for
mortality and major morbidity was constructed.
Results: There were 2315 esophagectomies performed by 73 participating centers. Hospital mortality was 63/
2315 (2.7%). Major morbidity (defined as reoperation for bleeding [n ¼ 12], anastomotic leak [n ¼ 261], pneu-
monia [n ¼ 188], reintubation [n ¼ 227], ventilation beyond 48 hours [n ¼ 71], or death [n ¼ 63]) occurred in
553 patients (24%). Preoperative spirometry was obtained in 923/2315 (40%) of patients. A forced expiratory
volume in 1 second<60% of predicted was associated with major morbidity (P ¼ .0044). Important predictors
of major morbidity are: age 75 versus 55 (P ¼ .005), black race (P ¼ .08), congestive heart failure (P ¼ .015),
coronary artery disease (P ¼ .017), peripheral vascular disease (P ¼ .009), hypertension (P ¼ .029), insulin-
dependent diabetes (P ¼ .009), American Society of Anesthesiology rating (P ¼ .001), smoking status (P ¼
.022), and steroid use (P ¼ .026). A strong volume performance relationship was not observed for the composite
measure of morbidity and mortality in this patient cohort.
Conclusions: Thoracic surgeons participating in the Society of Thoracic Surgeons General Thoracic Database
perform esophagectomy with a low mortality. We identified important predictors of major morbidity and mortal-
ity after esophagectomy for esophageal cancer. Volume alone is an inadequate proxy for quality assessment after
esophagectomy.5-7Earn CME credits at
http://cme.ctsnetjournals.org
Despite advances in the management of patients with esoph-
ageal cancer, esophagectomy remains an operation with
relatively high morbidity and mortality. Pulmonary compli-
cations in particular contribute to prolonged hospital stays
and poor patient outcomes.1,2 Numerous single-institution re-
ports, most with limited data sets, have attempted to identify
predictors of morbidity and mortality. Some factors, includ-
ing weight loss, functional status, smoking status, forced ex-
piratory volume in 1 second (FEV1), and age are generally
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The Journal of Thoracic and Caoperative induction therapy, are more controversial. To
date, however, there has been only 1 large, multi-institutional
prospective study of perioperative risk factors for esophagec-
tomy for cancer. Although based on clinical data reporting,
this study was limited to patients within the Veterans Admin-
istration system, a very select patient population not represen-
tative of the general US patient population.8 As such, the
collected variables were not always applicable to the usual
patient population (eg, ascites), and certain important out-
come measures (eg, anastomotic leak) were not recorded.
Reports from numerous administrative databases have
shown a substantial volume performance relationship for
esophagectomy.9,10 Many advocate using only volume to
judge quality of care. The danger of such a simplistic ap-
proach is that some surgeons will be unfairly judged when
volume is used as the sole proxy quality measure. This study
addresses the need for a morbidity and mortality model for
esophagectomy for participants in the Society of Thoracic
Surgeons General Thoracic Database.
PATIENTS AND METHODS
Society of Thoracic Surgeons Database
The Society of Thoracic Surgeons (STS) General Thoracic Database
(GTDB) was established in 1999 as a voluntary initiative to support the con-
tinuous quality improvement efforts of surgeons and hospitals. Participating
institutions receive twice-yearly feedback reports that describe each site’s
results in relation to other database participants. Although the database is
not currently audited, all participants sign a contract that requires completerdiovascular Surgery c Volume 137, Number 3 587
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SAbbreviations and Acronyms588ASA ¼ American Society of Anesthesiology
CAD ¼ coronary artery disease
CHF ¼ congestive heart failure
COPD ¼ chronic obstructive pulmonary
disease
FEV1 ¼ forced expiratory volume in 1 second
GTDB ¼ General Thoracic Database
NIS ¼ Nationwide Inpatient Sample
PVD ¼ peripheral vascular disease
RAR ¼ risk-adjusted rate
SEER ¼ Surveillance, Epidemiology, and
End Results
STS ¼ Society of Thoracic Surgeons
VA NSQIP ¼ Department of Veterans Affairs
National Surgical Quality
Improvement Program
BMI ¼ body mass indexreporting of all cases and prohibits selective reporting. Details of the STS
GTDB data collection instrument can be found on the STS website.11 Par-
ticipation in the STS GTDB requires initial institutional review board ap-
proval, but subsequent deidentified data analysis for quality improvement
purposes does not.
Patient Population
Between January 2002 and December 2007, there were 2391 esophagec-
tomies for primary esophageal cancer entered into the STS GTDB by 75 sur-
gical sites. Data from 2 sites (n ¼ 49 operations) were excluded because
these sites did not report outcomes consistently during the study period.
Also excluded were emergency operations (n ¼ 14) and patients younger
than 30 years (n ¼ 6), as well as cases with missing data for age (n ¼ 2)
or discharge mortality (n ¼ 5). The final study population consisted of
2315 operations from 73 participating sites.
Outcome Definitions
Postoperative events were those defined by the STS GTDB guidelines.11
Hospital mortality is defined as death during the same hospitalization as sur-
gery regardless of timing. We chose hospital mortality rather than 30-day
mortality because there were more deaths in the hospital mortality cohort
(63 vs only 50 at 3 days) and 7% of sites did not submit 30-day mortality
data. The hospital mortality of 2.7% (63/2252) after esophagectomy proved
too low to serve as an end point for comparing hospital performance. We
therefore decided to analyze a composite morbidity/mortality outcome.
Adverse outcome measure selection was on the basis of clinical judgment,
literature review, and preliminary data analysis. This outcome was defined
as the presence of 1 or more of the following postoperative conditions:
bleeding requiring reoperation, anastomotic leak requiring medical or surgi-
cal treatment, reintubation, initial ventilation> 48 hours, pneumonia, or
death. Twenty-four percent (553/2315) of patients exhibited 1 or more of
the defined morbidity events, and this clinically relevant composite outcome
measure proved satisfactory to model.
Selection of Covariates
Model variables were identified by reviewing 3 versions of the STS data
collection instrument (v1.3, v2.06, v2.07). Because the primary purpose of
the model was to adjust for case mix in making hospital comparisons, can-The Journal of Thoracic and Cardiovascular Surgdidate predictor variables were limited to preoperative patient factors that
were not directly modifiable by the surgeon or hospital. Variables were
excluded from consideration if they were not collected consistently across
all versions of the data collection instrument. Remaining variables were
screened based on a combination of literature review and informal empirical
analysis. Pulmonary functional variables (forced expiratory volume, diffus-
ing capacity for carbon monoxide) were excluded on the basis of excessive
(>50%) missing data. Prior cardiothoracic surgery was excluded based on
a priori clinical judgment and the lack of significant association with the
model end point in univariate analyses. All remaining variables were in-
cluded in the multivariable analysis and are listed in Table 3. Missing pre-
dictor values were managed using a combination of complete case analysis
and single and multiple imputation, as described in the Appendix. A sensi-
tivity analysis was conducted to determine whether inferences changed
depending on the method of handling missing data.
Multivariable Analysis
Multivariable logistic regression was used to estimate the relationship
between patient preoperative characteristics and the outcome of mortality
or major morbidity. All covariates were retained in the model and were
not added or removed based on a variable selection algorithm. Parameters
of the logistic model were estimated using generalized estimating equations
methodology to account for statistical dependence between outcomes of
patients at the same hospital. Discrimination of the model was assessed
by calculating the area under the receiver operating characteristic curve,
also known as the C-statistic. The method of bootstrap resampling was
used to correct the C-statistic for optimism.
Analysis of Volume Performance Association
To assess the association between STS participant volume and perfor-
mance, the model described above was subsequently altered to include
each participant’s average annual volume of esophagectomy procedures.
The average annual volume was calculated as 12 times the total number
of records from a site divided by the total number of months during which
the site submitted data.
Analysis of Hospital Performance Variation
To explore variation in hospital performance, the model described above
(without volume) was subsequently refit as a 2-level hierarchical model with
nesting of patients within participants. The hierarchical model included the
same set of patient factors described above, plus a set of random hospital-spe-
cific effects. The hospital-specific effects are interpreted as reflecting underlying
differences in performance that systematically increase or decrease risk of all
patients at the same hospital. Performance variation was summarized by cal-
culating hospital-specific risk-adjusted rates (RARs) of mortality or major
morbidity. The RAR is interpreted as the rate of mortality or major morbidity
that would be observed hypothetically for a participant if the participant per-
formed surgery on each patient in the STS database. If the risk-adjusted rate
is significantly different from the overall STS database average, this may be
interpreted as evidence of good or poor performance. Uncertainty surrounding
the estimated RAR was quantified by calculating Bayesian 95% probability
intervals. Details of the hierarchical model, including the calculation and inter-
pretation of RARs and probability intervals, are described in the Appendix.
Analysis was performed using S-Plus 6 (Insightful Corp, Seattle, Wash),
SAS 9.1 (SAS Institute, Cary, NC), and WinBUGS 1.4.1 (Freeware, http://
www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml and Imperial College of
Science, Technology and Medicine at St Mary’s, London).RESULTS
The average site-specific volume of esophagectomies
ranged from 1 to 83 cases per year. Patient characteristics
are seen in Table 1. The patients were almost all whiteery c March 2009
TABLE 1. Distribution of risk factors and frequency of adverse










Total 2315 100.0 553 23.9
Age (y)
<60 811 35.0 168 20.7 .045
60–64 411 17.8 96 23.4
65–69 399 17.2 93 23.3
70–74 324 14.0 79 24.4
75–80 260 11.2 82 31.5
>80 110 4.8 35 31.8
Gender
Male 1898 82.0 446 23.5 .335
Female 417 18.0 107 25.7
Race
White 2104 90.9 500 23.8 .007
Black 63 2.7 24 38.1
Other 106 4.6 24 22.6
Missing 42 1.8 5 11.9
Zubrod score
0, no symptoms 497 21.5 111 22.3 .086
1, fully ambulatory 1480 63.9 354 23.9
2, in bed<50% 134 5.8 45 33.6
3, in bed>50% and
<100%
59 2.5 18 30.5
4, bedridden 8 0.3 2 25.0
Missing 137 5.9 23 16.8
ASA
I 92 4.0 13 14.1 <.001
II 720 31.1 131 18.2
III 1226 53.0 330 26.9
IV 129 5.6 47 36.4
V 2 0.1 0 0.0
Missing 146 6.3 32 21.9
Body mass
index (kg/m2)
<25 648 28.0 160 24.7 .023
25–29 784 33.9 169 21.6
30–34 445 19.2 114 25.6
35 237 10.2 72 30.4
Missing 201 8.7 38 18.9
CHF
No* 2264 97.8 526 23.2 .006
Yes 51 2.2 27 52.9
CAD
No* 1881 81.3 407 21.6 <.001
Yes 434 18.7 146 33.6
PVD
No* 2183 94.3 498 22.8 <.001
Yes 132 5.7 55 41.7
Hypertension
No* 1177 50.8 236 20.1 .003












No* 1299 56.1 319 24.6 .427
Yes 1016 43.9 234 23.0
Steroids
No* 2275 98.3 538 23.6 .368
Yes 40 1.7 15 37.5
Prior cardiothoracic
operation
No* 2084 90.0 484 23.2 .098
Yes 231 10.0 69 29.9
Diabetes
No diabetes 1883 81.3 425 22.6 .010
Diabetes, noninsulin 287 12.4 88 30.7
Diabetes, insulin 86 3.7 32 37.2
Missing 59 2.5 8 13.6
Renal function
No renal insufficiency 2224 96.1 530 23.8 .280
Creatinine  2 46 2.0 15 32.6
Dialysis of any type 3 0.1 2 66.7
Missing 42 1.8 6 14.3
Cigarette use
No 579 25.0 115 19.9 .024
Yes 1731 74.8 437 25.2
Missing 5 0.2 1 20.0
Stage
1 494 21.3 116 23.5 .104
2a 442 19.1 122 27.6
2b 96 4.1 25 26.0
3 512 22.1 123 24.0
Missing 771 33.3 167 21.7
Percent FEV1
<60 89 3.8 32 36.0 <.001
60–79 189 8.2 63 33.3
80 645 27.9 144 22.3
Missing 1392 60.1 314 22.6
Percent DLCO
<60 119 5.1 45 37.8 <.001
60–79 249 10.8 68 27.3
80 351 15.2 76 21.7
Missing 1596 68.9 364 22.8
ASA, American Society of Anesthesiology; CAD, coronary artery disease; CHF,
congestive heart failure; DLCO, diffusing capacity for carbon monoxide; FEV1, forced
expiratory volume in 1 second; PVD, peripheral vascular disease. *There are no missing
data reported because data were collected in a check box (check all that apply) format.
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S(91%) and mostly men (82%). The majority had significant
medical comorbidities. Induction therapy was given in
almost half of the patients. Major morbidity (defined as reop-
eration for bleeding [n ¼ 12], anastomotic leak [n ¼ 261],
pneumonia [n¼ 188], reintubation [n¼ 227], ventilation be-
yond 48 hours [n ¼ 571], or death [n ¼ 63]) occurred in 553/
2315 patients (24%). Overall, 57% of patients (1327/2315)
suffered at least 1 adverse event after esophagectomy. Onlyrdiovascular Surgery c Volume 137, Number 3 589
TABLE 2. Frequency of intraoperative and postoperative events in patients after esophagectomy for cancer with and without morbidity




major morbidity P value
Pulmonary embolus 0.9% (22/2315) 0.5% (8/1762) 2.5% (14/553) <.001
DVT 2.0% (47/ 2315) 1.3% (23/1762) 4.3% (24/553) <.001
Tracheostomy 4.0% (92/2315) 0.3% (6/1762) 15.6% (86/553) <.001
Atrial fibrillation 17.5% (406/2315) 14.9% (262/1762) 26.0% (144/553) <.001
MI 0.7% (15/2315) 0.3% (6/1762) 1.6% (9/553) <.001
Intraoperative blood transfusion* 7.2% (138/1926) 6.3% (91/1446) 9.8% (47/480) .131
Postoperative blood transfusion* 15.9% (306/1926) 11.8% (171/1446) 28.1% (135/480) <.001
RLN paralysis 2.3% (52/2315) 1.5% (27/1762) 4.5% (25/553) <.001
Renal failure 2.6% (60/2315) 0.7% (13/1762) 8.5% (47/553) <.001
Sepsis 3/2% (75/2315) 0.7% (12/1762) 11.4% (63/553) <.001
Chylothorax 1.9% (45/2315) 1.9% (33/1762) 2.2% (12/553) .988
DVT, Deep venous thrombosis; MI, myocardial infarction; RLN, recurrent laryngeal nerve. *Only available in STS data version 2.07.
TABLE 3. Predictors of major morbidity after esophagectomy for
cancer
Odds ratio
Variable Estimate 95% CI P value
Age (y)
65 vs 55 1.04 0.90–1.20 .593
75 vs 55 1.24 1.07–1.45 .005
Female 1.20 0.92–1.55 .177
Black race 1.76 0.93–3.34 .082
CHF 2.3 1.18–4.49 .015
CAD 1.31 1.05–1.65 .017
PVD 1.55 1.12–2.14 .009
Zubrod score
1 vs 0 1.13 0.98–1.30 .100
2 vs 0 1.27 0.95–1.69 .100
3 vs 0 1.43 0.93–2.20 .100
4 vs 0 1.62 0.91–2.86 .100
ASA class
2 vs 1 1.26 1.10–1.46 .001
3 vs 1 1.60 1.20–2.13 .001
4 vs 1 2.02 1.32–3.10 .001
5 vs 1 2.56 1.45–4.52 .001
Insulin diabetes 1.19 1.05–1.36 .009
Hypertension 1.16 1.01–1.32 .029
Steroids 1.81 1.07–3.06 .026
Renal dysfunction 0.95 0.55–1.64 .846
Induction therapy 0.93 0.77–1.11 .424
Cigarette usage 1.27 1.03–1.56 .022
BMI (per 5-unit increase) 1.02 1.00–1.03 .123
Time trend (per 5 y) 1.29 0.93–1.80 .133
ASA, American Society of Anesthesiology; BMI, body mass index; CAD, coronary
artery disease; CHF, congestive heart failure; CI, confidence interval; PVD, peripheral
vascular disease.
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Sa small number of patients required a return to the operating
room to manage an adverse event (168/2315, 7.3%) but the
majority of those with major morbidity did (97/553, 57.7%;
P<.0001 when compared with those without major morbid-
ity). The hospital discharge mortality was 2.7% (63/2315).
The hospital discharge mortality in those with major morbid-
ity was 11% (63/553), whereas it was 0 in those without ma-
jor morbidity (P<.0001). The overall median length of stay
was 10 days, and the mean was 14 days. The mean length of
stay was 10.6 days in patients without major morbidity and
25.6 days in those with major morbidity (P< .0001).
The univariate associations between patient characteris-
tics and the end point of mortality or major morbidity are
seen in Table 1. Age, medical comorbidities, and steroid
use are predictors of major morbidity and mortality. In con-
trast, induction therapy was not statistically associated with
major morbidity. Both cigarette use and significant chronic
obstructive pulmonary disease (COPD; FEV1 < 60%)
were associated with major morbidity. Race and the Zubrod
score were associated with a trend in major morbidity and
mortality.
Intraoperative blood transfusion only occurred in 6%
(138/2315) of patients and was associated with a trend in
morbidity in univariate analysis (P ¼ .11). Operative ap-
proach was recorded as transhiatal in 415, thoracoabdominal
in 139, Ivor-Lewis in 215, thoracotomy-only in 85, 3-hole
(McKeowen) in 45, and minimally invasive in 89. Operative
approach could not be determined in 1327 patients (previous
versions of the database did not collect operative approach).
Table 2 details other intraoperative and postoperative
events in patients after esophagectomy with and without
major morbidity. Important postoperative events, beyond
what were included in the morbidity model, were more com-
mon in those with major morbidity. These included the need
for postoperative blood transfusion, recurrent laryngeal
nerve paralysis, renal failure, and sepsis.
The multivariable association between preoperative patient
factors and the end point of mortality or major morbidity is590 The Journal of Thoracic and Cardiovascular Surgsummarized in Table 3. The bootstrap-adjusted C-statistic
was 0.621. Statistically significant predictors included age
(75 vs 55), congestive heart failure (CHF), coronary artery
disease (CAD), peripheral vascular disease (PVD), hyperten-
sion, American Society of Anesthesiology (ASA) rating, in-
sulin-requiring diabetes, steroid use, and cigarette smoking.ery c March 2009
FIGURE 1. Risk-adjusted rates of morbidity after esophagectomy for cancer among Society of Thoracic Surgeons sites. The graph excludes participants that
contributed fewer than 6 operations to the analysis data set. The participant identifiers are anonymous codes and do not denote an abbreviation for a center’s
name.
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Appendix. When average annual volume was included in the
regression analysis as a linear covariate, the odds ratio esti-
mate for a 10-unit decrease in volume was 1.09 (95% confi-
dence interval 0.98–1.20; P ¼ .10).
Figure 1 examines the hospital-specific risk-adjusted rates
of mortality and morbidity among the 44 sites that had atFIGURE 2. Comparison of adjusted and unadjusted morbidity rates versus
participant average annual volume of esophagectomies for lung cancer.
Each dot and square represent 1 participant site. The graph excludes partic-
ipants that contributed fewer than 6 operations to the analysis data set.
The Journal of Thoracic and Caleast 1 esophagectomy per year (29 sites had<6 esophagec-
tomies in the 6-year study period and were excluded from
this particular analysis). The probability intervals of some
of the best-performing sites (on the left side) do not overlap
with some of the sites with worse outcomes (on the right
side), indicating there is a significant difference in perfor-
mance among some sites.
The relationship between major morbidity and volume
among the same 44 sites is plotted in Figure 2. The average
annual case volume at these 44 sites ranged from 1 to 83 in
the 6-year reporting period. Note there is no strong volume
performance relationship in the graph, a finding that is con-
sistent with the nonsignificant volume effect in our multivar-
iable regression analysis.
DISCUSSION
STS sites that participate in the GTDB perform esopha-
gectomy for cancer with relatively low mortality and mor-
bidity. Patients who experience adverse events after
esophagectomy have a marked increase in length of stay
and mortality. We identified multiple risk factors for
combined morbidity and mortality after esophagectomy
for cancer: age, CHF, CAD, PVD, diabetes, hypertension,
use of steroids, smoking status, and ASA score. Using these
results, we constructed a risk model for esophagectomy that
allows individual STS sites to compare their results with
others as a means toward quality improvement. In contrast
to previous studies using administrative data,9,10 we didrdiovascular Surgery c Volume 137, Number 3 591
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composite measure of morbidity and mortality among STS
sites that participate in the GTDB.
The operative mortality among sites that participate in the
STS GTDB was 2.7%, which is markedly lower than recent
reports based on large nationwide data sets.8,12,13 A recent
report from the Department of Veterans Affairs National Sur-
gical Quality Improvement Program (VA NSQIP) recorded
a mortality of 9.8% among 1777 patients who had esophagec-
tomy.8 Another report based on the national Surveillance,
Epidemiology, and End Results (SEER) Medicare-linked
database recorded a mortality of 11% among 868 patients
who had esophagectomy.12 Additionally, the average length
of stay (14 days) in our patient cohort was markedly shorter
than the average length of stay (21 days) in the SEER patient
cohort. These differences may reflect overall better quality
provided by surgeons who are board certified and participate
in a voluntary quality improvement initiative.
Several factors likely contribute to the lower observed
morbidity and mortality of the STS GTDB. Participation
is encouraged but not mandated in the STS GTDB, which
leads to selection bias regarding participants. As such,
early reporters to the GTDB are likely to be clinicians
with a particular interest in quality improvement. Second,
given the early academic nature of the database, partici-
pants possibly overrepresent academic medical centers. In
addition, academic medical centers typically have more re-
sources to support ill patients and experience with complex
procedures such as esophagectomies. Last, the database
was initially limited to board-certified thoracic surgeons,
who have been shown to have better outcomes after esoph-
agectomy14 The results achieved within the context of the
STS GTDB are clearly superior to those reported for the
entire US population and are hence not representative of
the entire esophageal cancer patient population. It is likely
that the ‘‘best’’ surgeons are overrepresented within this
data set.
Our analysis identified 8 predictors of morbidity/mortality
following esophagectomy for cancer. Age is an intuitive risk
factor and has been previously identified as an important
predictor of outcome following esophagectomy.1,2 A large
single-institution report from a center of excellence, how-
ever, has suggested that age per se should not be a limiting
criteria for esophagectomy.15 This report suggests that the
use of stringent patient selection criteria in elderly patients
can mitigate their increased risk, a conclusion with which
we agree. CHF was found to be a third important predictor
but was rarely present among our patients (51/2315,
2.2%), likely due to careful case selection. Given the large
fluid shifts that occur after esophagectomy, it is not surpris-
ing that CHF is a risk factor. Careful patient selection,
preoperative medical optimization, and conscientious post-
operative care could all improve outcomes in these patients.
PVD has not been well studied, but a recent report using the592 The Journal of Thoracic and Cardiovascular SurgNationwide Inpatient Sample (NIS) database found PVD to
be associated with increased risk.13 In our data set, PVD was
again quite uncommon, occurring in only 5.7% (132/2315)
of our patients, but was strongly associated with increased
morbidity. It is likely that the end-stage effects of both smok-
ing and unfavorable cardiovascular biology lead to worse
outcomes. Proper patient selection and medical optimization
of cardiac risk would seem to be important strategies to min-
imize perioperative risk. Hypertension and CAD are other
intuitive risk factors in this patient population and have
not been reported before.
Insulin-requiring diabetes has been previously identified
by the VA NSQIP model and other reports as a risk factor
for both morbidity and mortality following esophagectomy
for cancer.8,16 Diabetic patients requiring insulin were again
uncommon in our study population, representing only 3.7%
(86/2315) of our patients. Again, proper preoperative medi-
cal optimization and careful diabetic management after oper-
ation likely lead to optimal outcomes. A history of smoking
was present in the majority of our patients (1731/2315,
75%) and was associated with worse outcomes. We were
not able to tease out outcome differences depending on
when or if patients stopped smoking. Certainly active smok-
ing should be strongly discouraged and patients referred to
smoking cessation counseling well before an esophagec-
tomy. Others have reported that significant COPD (either
the presence of the diagnosis or a low FEV1) is associated
with increased morbidity and mortality after esophagec-
tomy.2,8,17 Most of our patients did not have FEV1 recorded
(we are unsure if this was an oversight or if it was not per-
formed as part of preoperative testing) but among those
who did (923/2315, 40%), it was highly predictive of
postoperative morbidity in univariate analysis. Given that
pulmonary complications are the most common major
complications after esophagectomy, and in particular the
complications most likely to lead to death, it is intuitive
that significant COPD leads to worse outcomes. We need
to encourage surgeons to increase the frequency of ordering
pulmonary spirometry prior to esophagectomy to both better
risk-stratify patients and to identify patients who might ben-
efit from preoperative pulmonary optimization.
The ASA rating, a surrogate for medical comorbidities,
was also strongly associated with morbidity. More complex
patients (based on other complexity scoring systems) have
been previously reported as more likely to have increased
morbidity after esophagectomy.1,8
An important risk factor for combined morbidity and mor-
tality, black race, has not been evident in many other large
multi-institutional database reports.8,12 One recent report
from the NIS database, however, concurs with our data; in
this data set, blacks had an increased risk of mortality after
esophagectomy.13 As African-Americans constituted only
2.7% (63/2315) of our patient population, the validity of
our observation needs to be confirmed by other larger dataery c March 2009
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observed with greater frequency in the African-American
population, will ultimately explain this increased risk. The
issue of obesity is particularly relevant now that the majority
of patients presenting with esophageal cancer are over-
weight and have Barrett’s adenocarcinoma from prolonged
reflux. The mean body mass index (BMI) in our patients
was 28 (overweight, close to obese). We found obesity to
be associated with a trend in increased morbidity. Previous
reports are conflicting about obesity, with some suggesting
it is an important risk factor and others not.13,17,18 The larg-
est report suggests that obesity is associated with more spe-
cific complications (such as blood loss and recurrent
laryngeal nerve injury) but is not associated with increased
mortality.18 This report is partially limited by the fact that
all operations were transhiatal esophagectomies. It is intui-
tive that the very obese would have longer, more difficult
operations and have impaired mobility and pulmonary func-
tion early after operation. Further investigation into the type
of operative approach (transhiatal versus a thoracotomy) is
warranted to ascertain if operative risk in the very obese
might be mitigated by a nonthoracotomy approach.
We did not find induction therapy to be predictive of in-
creased major morbidity. Some previous reports suggest
an increased risk, and others do not.5-8 To date, our report
is by far the largest and most geographically representative
of the entire United States; however, it still suffers from
the previously mentioned potential bias that STS GTDB par-
ticipants may be select high-performing clinicians not fully
representative of all surgeons in the United States. Regard-
less, our data suggest that careful patient selection and man-
agement can allow this therapy to be given if necessary
without increased morbidity.
Importantly, we did not find a strong volume perfor-
mance relationship for the composite end point of major
morbidity and mortality after esophagectomy. Figure 2
does not show a strong relationship between volume and
composite mortality/morbidity despite a wide variation in
average annual volume (1 to 83 patients per year). Numer-
ous previous reports based on administrative data sets have
demonstrated a volume performance relationship in esoph-
agectomy for mortality.9,10 As previously noted, several re-
ports also indicate a volume performance relationship with
postoperative morbidity as well, which is not surprising
given that complications are what lead to mortality.19,20
Many have even suggested using volume as a quality surro-
gate for esophagectomy (eg, the Leapfrog Group) to direct
referrals to appropriate surgeons. Our analysis, using a com-
posite end point of mortality or major morbidity, does not
support this approach, at least as applied to surgeons who
participate in the STS GTDB. This likely reflects the skill
of surgeons at such centers and the overall level of support-
ive care available to assist in the perioperative management
of these complex patients. It must be acknowledged thatThe Journal of Thoracic and Cathese results cannot necessarily be extrapolated to other
scenarios, such as non–Board-certified thoracic surgeons
who do not participate in the STS GTDB. It is important
to emphasize that we did not study mortality alone like pre-
vious reports on the volume performance relationship. We
can state, however, that the volume performance relation-
ship seems to be partially mitigated among participants in
the STS GTDB with a composite measure of morbidity
and mortality.
There are several limitations of our report. Most impor-
tantly, this database represents a select group of surgeons
from within the STS who are interested in quality improve-
ment in an altruistic fashion. There is nothing financial to be
gained from database participation, and in fact it is relatively
expensive to participate in it. The surgeons who participate
currently are likely to be ‘‘first adopters’’ and hence are
probably not representative of the entire US surgical com-
munity. The database is currently not audited for data qual-
ity, although there are plans in the future for this to occur.
However, there is no reward for any potential ‘‘gaming’’
the system, so it is unlikely that this is a systematic problem.
There were more missing data than we would have liked,
especially in the staging and pulmonary function data. We
did analyze our data set with and without these data and there
was no substantial difference in results, however. We did not
collect data with regard to rehospitalization related to the
esophagectomy, so it is likely we missed some late compli-
cations of esophagectomy. Last, we analyzed in-hospital
mortality, so it is possible that we missed some early deaths
that occurred after hospital discharge.
We conclude that thoracic surgeons participating in the
STS GTDB perform esophagectomy with a low mortality.
Age, medical comorbidities, smoking status, and significant
obstructive lung disease are predictors of major morbidity
and mortality after esophagectomy for esophageal cancer.
Prognostic factors identified in this analysis will help to pre-
dict risk in individual patients and guide quality improve-
ment through risk-adjusted feedback. Volume alone is an
inadequate proxy for quality assessment after esophagec-
tomy. Modern multi-institutional prospectively collected
clinical data sets with sophisticated risk-adjustment method-
ology are required to compare results.References
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The following patient-level covariates were included in
the multivariable analysis: age (modeled as a 2-phase linear
function with a change of slope at 65 years); gender (female/
male); race (African-American/non–African-American);
CHF (yes/no); CAD (yes/no); PVD (yes/no); Zubrod Score
(5 categories, 0–4, modeled as linear); ASA class (5 cate-
gories, 1–5, modeled as linear); insulin-dependent diabetes
(yes/no), hypertension (yes/no), steroid use (yes/no), renal
dysfunction (creatinine>2 or dialysis/none), induction ther-
apy (chemotherapy or thoracic radiation/none), smoking
(ever/never), BMI (linear), year of surgery (linear). These
covariates were selected based on a combination of a priori
clinical judgment and an empirical investigation of missing
data frequency. Variables were not added or removed from
models based on an automated variable selection procedure.
In addition to patient factors, all models were estimated with
and without the inclusion of a linear term for the effect of
hospital volume of esophagectomy procedures.
Ordinary Logistic Regression Model
The relationship between patient predictor variables and
morbidity was examined first using ordinary logistic regres-
sion and subsequently using hierarchical logistic regression.
The ordinary logistic model has the form:
logðpi=½1piÞ ¼ b0þ b1x1i þ.þ bqxqi
where pi denotes the probability of major morbidity for the
ith patient; xqi denotes the value of qth covariate for the ith
patient, and b1, . . . , bq denote unknown parameters to be
estimated from the data. The term xqi represents quantitative
risk factors such as age and binary indicator variables (eg,
1 ¼ male, 0 ¼ female). Parameters of the ordinary logistic
regression model were estimated using generalized estimat-
ing equations methodology. This approach results in esti-
mates that are similar to conventional maximum likelihood
estimation, but the standard errors are adjusted to accountfor statistical dependence (clustering) between outcomes
of patients at the same hospital.Hierarchical Logistic Regression Model
To study between-hospital variation in risk-adjusted out-
comes, the model described above was subsequently refit as
a 2-level hierarchical model with patients nested within
participants. Unlike ordinary logistic regression, this model
included a set of hospital-specific random effects. The form






 ¼ b0þ b1x1ji þ.þ bqxqj þ ej
where pji denotes the probability of major morbidity for the
ith patient at the jth hospital; the xqji denotes the covariate
values for the ith patient at the jth hospital; and ej denotes
a (random effect) intercept parameter for participant j.
Parameters of the random effects logistic model were esti-
mated in a Bayesian framework using WinBUGS software.
In a Bayesian analysis, inferences about unknown quantities
are expressed in terms of probabilities. For example, it is
possible to report the probability that the coefficient for
a given variable is larger than 0 or the probability that a hos-
pital’s random effect parameter is greater than 0.
Hospital-specific RARs of mortality or major morbidity
were calculated using the estimated hospital-specific random
effects parameters. The risk-adjusted rate is a prediction of
what a given hospital’s actual morbidity rate would be if
all patients in the STS database received surgery at that hos-
pital. The risk-adjusted rate of the hth hospital, denoted









where nj denotes the number of patients at hospital j, and N ¼
n1þn2þ. . .þnq. The subscript h in eh denotes that the random
effect for the hth hospital is held constant in the summationery c March 2009
Wright et al General Thoracic Surgeryand is substituted into the probability formula for all patients
in all hospitals. Estimated RAR values were plotted along
with a 95% Bayesian probability intervals. The Bayesian
probability interval has the interpretation that it is 95% likely
that the true risk-adjusted rate lies between the upper and
lower limits of the reported interval. If the probability
interval includes the STS average rate, then the hospital’s
performance is not statistically distinguishable from average.TABLE A1. Variables and regression coefficients for the logistic
regression model reported in Table 3
Model variable Coefficient Definition of model variable
Constant 2.8341 Constant
Age function 1 0.0179 ¼ max(65-age, 0)
Age function 2 0.0039 ¼ max(age-65, 0)
Female 0.1789 ¼ 1 if patient is female, ¼ 0 otherwise
Black 0.5660 ¼ 1 if patient is black, ¼ 0 otherwise
CHF 0.8332 ¼ 1 if patient has CHF, ¼ 0 otherwise
CAD 0.2737 ¼ 1 if patient has CAD, ¼ 0 otherwise
PVD 0.4359 ¼ 1 if patient has PVD, ¼ 0 otherwise
Zubrod 0.1199 Ordinal variable taking the values 0, 1,
2, 3, 4
ASA 0.2350 Ordinal variable taking the values 1, 2,
3, 4, 5
Insulin diabetes 0.1754 ¼ 1 if patient has insulin-dependent
diabetes, ¼ 0 otherwise
Hypertension 0.1472 ¼ 1 if patient has hypertension, ¼
0 otherwise
Steroids 0.5944 ¼ 1 if history of steroid usage, ¼
0 otherwise
Renal dysfunction 0.0544 ¼ 1 if patient has creatinine>2.0 or
dialysis, ¼ 0 otherwise
Induction Tx 0.0744 ¼ 1 if chemotherapy or radiation
preoperatively, ¼ 0 otherwise
Cigarettes 0.2381 ¼ 1 if history of smoking, ¼
0 otherwise
BMI 0.0150 Continuous variable
Year* 0.0511 ¼ Year of surgery minus 2002
ASA, American Society of Anesthesiology; BMI, body mass index; CAD, coronary
artery disease; CHF, congestive heart failure; PVD, peripheral vascular disease; Tx,
treatment. *To avoid extrapolation, future model estimates should be calculated as




Missing data methods for ordinary logistic model. Miss-
ing predictor values in the ordinary logistic model were man-
aged using a combination of complete case analysis and
single imputation. For age, gender, and year of surgery,
patients with missing data were excluded from the analysis
(ie, complete case analysis). This approach was adopted
because nonmissing data on these 3 fields is a basic inclusion
criterion for all reports produced by the STS data warehouse.
For comorbidity variables (CHF, CAD, insulin diabetes,
hypertension, steroid use, renal dysfunction, induction ther-
apy, smoking), missing values were defaulted to the negative
(ie, single imputation). The decision to use single imputation
was based on consideration of the STS data collection instru-
ment. Comorbidities in STS are collected using a check box
format. Because no data entry is required unless a comorbidity
is present, there is no opportunity to distinguish the absence of
a comorbidity from missing data. Thus, when data are
received into the warehouse that contain a null value, it is
not clear whether this null value indicates missing data or
the absence of a comorbidity, and in fact this may depend
on the software that was used for collecting the data. Because
missing data are not distinguishable from null values, the only
option for analysis is to model yes versus no or missing,
which is equivalent to imputing missing data to the negative.
For the remaining variables, missing data were imputed to the
median (BMI) or mode (race, Zubrod score, ASA class.)
Missing data methods for hierarchical model. To ex-
plore whether results change depending on the method of
handling missing data, 2 approaches of handling missing
data were implemented and compared to one another. In
both approaches, age, gender, year of surgery, and comor-
bidities were imputed using the approach described above.
For the remaining variables (race, Zubrod score, ASA class,
BMI), missing data were either imputed using the method
described above (approach 1) or were imputed using
a Bayesian multiple imputation model (approach 2). To
implement approach 2, the probability distribution of race,
Zubrod score, ASA class, and BMI was approximated as
a multivariate normal distribution, and the mean of each
variable was modeled as a linear function of the following
variables: age, CHF, hypertension, induction therapy, ciga-
rette usage, year of surgery, and presence of postoperative
major morbidity. Parameters of the imputation model wereThe Journal of Thoracic and Caestimated jointly (in the same Markov Chain Monte Carlo
procedure) with the parameters of the model predicting ma-
jor morbidity. At each iteration, covariate values for patients
with missing data were randomly sampled from the posterior
predictive distribution and substituted into the model for the
relationship between covariates and morbidity. Because the
imputation model uses a multivariate normal distribution,
the imputed values are continuous rather than categorical.
Following the advice of Allison and others, the imputed ver-
sions of race, Zubrod score, and ASA class were left as con-
tinuous variables and were not rounded to integers. The final
model results were obtained by averaging across simulation
iterations. The impact of the 2 missing data methods was
assessed by comparing odds ratios obtained under approach
1 versus approach 2. For each covariate, the estimated odds
ratio changed by less than 3% (on a relative scale) depending
on the choice between approach 1 and approach 2. Because
the results were fairly insensitive to the choice of missing
data method, the simpler method (approach 1) was adopted.Model Coefficients
Variables and regression coefficients for the model in
Table 3 are summarized in Table A1.rdiovascular Surgery c Volume 137, Number 3 595




Dr J. Luketich (Pittsburgh, Pa). Dr Wright, that was an excel-
lent presentation, and I congratulate you and your colleagues on
your efforts to utilize the STS database, which includes close to
2000 cases of esophagectomy, to create a model of perioperative
risk. One very important finding of your study, as you point out,
is that thoracic surgeons participating in the STS database have
a markedly lower mortality rate of only 2.5% compared with the
Medicare database showing alarming mortality rates between 8%
and 23%. I have several questions about your study.
What is the quality control of the data collection of the STS data-
base? Are charts periodically audited by the STS during site visits?
Along these lines, has your statistician voiced concerns about includ-
ing the pulmonary function data, with fewer than 40% of patients hav-
ing reported spirometry yet the finding of an overall correlation with
outcome? And I wonder if you could comment specifically on which
morbidities that the lower FEV1 was associated with. And has this
influenced your practice? If you encounter a patient with an FEV1
<60%, are you excluding them from esophagectomy?
Dr Wright (Boston, Mass). Thank you for that question. Cur-
rently, the STS does not audit the data in their database. This is
a new database, in existence for only 6 years. You have to remem-
ber that the cardiac database, in existence for over 15 years, has
only been audited since 3 years ago, I believe. Their initial audit,
I think, was recognized as a success, indicating a less than 10% var-
iation in data elements. We anticipate the same results, but we have
not started that yet. It is clearly something we need to do.
We specifically excluded the use of pulmonary function tests in
our multivariate model because only 40% of our patients had pul-
monary function tests performed. Thus we only did a univariate
analysis of pulmonary function tests. I think that was an honest
way to treat that as we had so much missing data. Certainly, we
encourage surgeons to enter these data, because this is clearly going
to be an important risk factor.
Dr J. Luketich. Thank you. Second question. How serious was
the missing data problem with other variables? And I think you
have answered the other questions about the auditing plans. But
was the rate of missing variables of key comorbidity and outcome
variables of concern?
DrWright. Well, missing variables are always of concern to the
people looking at the database, but I think they were within reason.
For race, age, and gender, there were no missing variables. BMI
was 13%; cigarette smoking, 13%; diabetes, 5%; peripheral vascu-
lar disease, 13%. The rate of missing variables for outcome mea-
sures was<3%.
Dr. Luketich.My final question is in regards to the lack of a vol-
ume/outcome relationship for the number of esophagectomies per-
formed annually in each center. Your analysis included 40 of the 68
sites, and as I understand it, 28 sites performing fewer than 5 esoph-
agectomies per year were excluded from the analysis. I wonder if the
results would be similar if all sites were included? It would seem like
the hospitals with the very lowest numbers of esophagectomies an-
nually are the very hospitals we want to examine when it comes to
low volume of index cases and high complication and death rates.
Did you analyze and correct for other factors such as surgeon vol-
ume and specialty training? And do you think that the requirement
for thoracic board certification and performance of esophagecto-
mies in academic medical centers influence your findings?596 The Journal of Thoracic and Cardiovascular SurgDr Wright. That is an excellent question, a 2-part question. In
answer to the first part, our statisticians thought it was not statisti-
cally valid to include sites that had fewer than 1 esophagectomy per
year, because they were looking on a per-year basis. It would be in-
teresting to go back and see what those results were. But certainly
the sites to the right on my graph show 1 case a year versus 60 cases
a year. There is not a lot of difference.
Certainly I don’t propose that this volume/performance relation-
ship is true of all of America. The STS thoracic database partici-
pants are very select. They belong to the STS, they are board
certified, and they are very interested in quality improvement,
and I think that is why the results are so good.
Dr S. DeMeester (Los Angeles, Calif). Cam, thank you very
much for that interesting presentation and data. Just a quick ques-
tion. Did you analyze induction therapy as either yes or no, they
had it or didn’t have it, or did you stratify by the amount of radia-
tion? As you know, it has been demonstrated that high radiation
doses seem to be associated with the risk of increased morbidity
or mortality.
Dr Wright. That is another good question, and we currently in
our data field only collect radiation as yes or no. So we could not do
that stratification.
Dr J. Benfield (Los Angeles, Calif). Many esophagectomies are
done by general surgeons. Do you see any way to gather meaning-
ful data to compare outcomes of general surgeons with those of tho-
racic surgeons?
Dr Wright. Well, I believe that paper has already been written
by Mark Orringer’s group at the University of Michigan, and they
did show that there was a modest improvement in results if you
were a board-certified thoracic surgeon as opposed to a general
surgeon.
Dr T. Karamlou (Portland, Ore). Two quick questions. One,
what was the conduct of the esophagectomies? Were these transhia-
tal, transthoracic, Ivor-Lewis, laparoscopic, 3 fields? And number
2, how is the diagnosis of some of the comorbidities arrived at, spe-
cifically pneumonia? Was this just a yes/no, or were there strict cri-
teria for establishing this as you used it as one of your composite
end points?
Dr.Wright. Pneumonia is defined in the database. It is a standard
definition of a white count, fever, and a change in sputum. All the
definitions are standardized. We did collect what type of esopha-
gectomy was done, and transhiatal was by far and away the com-
monest esophagectomy performed. But all varieties were looked
at, including Ivor-Lewis and the 3-hole type. We did not stratify
outcome according to esophagectomy type.
Dr N. Altorki (New York, NY). Cam, I enjoyed your presenta-
tion. I was wondering why you did not include in the measure of
morbidity electrical instability, atrial arrhythmias, and this sort. In
our experience, it has been the cause of major morbidity and pro-
longation of the hospital stay, and why was that not entered in
your model?
Dr. Wright. That was a clinical judgment decision in terms of
how major is major. We are aware that atrial fibrillation is a marker
for other bad things happening. Most serious events are respiratory
events, and so we were really focused on pulmonary complications
and morbidity and death after esophagectomy. But I take your point
that it is a judgment call.ery c March 2009
